Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Non-Current Liabilities: 2015-2025

Historic Other Non-Current Liabilities for Editas Medicine (EDIT) over the last 6 years, with Sep 2025 value amounting to $4.7 million.

  • Editas Medicine's Other Non-Current Liabilities rose 42.88% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 42.88%. This contributed to the annual value of $3.1 million for FY2024, which is 70.67% up from last year.
  • Editas Medicine's Other Non-Current Liabilities amounted to $4.7 million in Q3 2025, which was up 2.09% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Other Non-Current Liabilities registered a high of $6.4 million during Q1 2025, and its lowest value of $1.8 million during Q4 2023.
  • For the 3-year period, Editas Medicine's Other Non-Current Liabilities averaged around $3.9 million, with its median value being $3.6 million (2024).
  • Data for Editas Medicine's Other Non-Current Liabilities shows a peak YoY surged of 83.21% (in 2025) over the last 5 years.
  • Editas Medicine's Other Non-Current Liabilities (Quarterly) stood at $1.8 million in 2023, then skyrocketed by 70.67% to $3.1 million in 2024, then skyrocketed by 42.88% to $4.7 million in 2025.
  • Its Other Non-Current Liabilities stands at $4.7 million for Q3 2025, versus $4.6 million for Q2 2025 and $6.4 million for Q1 2025.